AVASTIN – bevacizumab 25 mg/mL intravenous solution

Genentech Inc

anaplastic astrocytoma; diabetic macular edema; PD-L1 positive, EGFR-negative, ALK-negative metast NSCLC; epithelial ovarian cancer; central retinal vein occlusion with macular edema; branch retinal vein occlusion with macular edema; neovascular age-related macular degeneration; nonsquamous non-small cell lung cancer; glioblastoma multiforme; metastatic renal cell carcinoma; metastatic colorectal cancer; liver cell carcinoma; carcinoma of cervix

nonsquamous non-small cell lung cancer; neovascular age-related macular degeneration; PD-L1 positive, EGFR-negative, ALK-negative metast NSCLC; branch retinal vein occlusion with macular edema; metastatic colorectal cancer; epithelial ovarian cancer; liver cell carcinoma; anaplastic astrocytoma; carcinoma of cervix; diabetic macular edema; glioblastoma multiforme; metastatic renal cell carcinoma; central retinal vein occlusion with macular edema

Fridge (2-8°C)